Podcasts about revance therapeutics

In this episode, Jim Garrity highlights three brand new deposition-related court rulings. The first presents the question of whether witnesses and their counsel can be prohibited from discussing the witnesses' testimony during recesses. The second addresses the propriety of asking foundational questions of privilege-bearing deponents to determine if the assertion of privilege is legitimate; the opinion explains what "foundational" questions are, gives examples, and details the procedure for deposing such witnesses and then presenting the issue to a court for decision. The third case in the spotlight highlights an avoidable problem when a lawyer seeks to depose an individual who has already testified in a 30(b)(6) capacity. Citations to the cases appear in today's show notes. Thanks for listening.SHOW NOTESVillareal v. Texas, Case No. 24-557, __ US __ (Apr. 7, 2025) agreeing to review ruling denying criminal defendant's request to confer about his testimony with his counsel during overnight breaks) petition for writ of certiorari at https://www.supremecourt.gov/DocketPDF/24/24-557/331695/20241113121417971_cert%20petition%20Villarreal%20v%20Texas.pdf; Brief in Opposition at https://www.supremecourt.gov/DocketPDF/24/24-557/348537/20250225093718236_250219a%20BIO%20for%20efiling.pdf; Reply Brief at https://www.supremecourt.gov/DocketPDF/24/24-557/351275/20250305130135816_cert%20reply%2024-557%20Villarreal%20v%20Texas.pdfAllergan, Inc. et al. v. Revance Therapeutics, Inc., No. 3:23-cv-00431, 2025 WL 1006372 (M. D. Tenn. Apr. 3, 2025) (outlining the procedure for questioning witnesses claiming privilege, and holding that foundational questions about the allegedly privileged communications must be allowed to determine whether a privilege exists)In re Social Media Adolescent Addiction/Personal Injury Products Liability Litigation, Case Number 22–MD–03047–YGR (PHK), 2025 WL 1009362 (N. D. Calif. Apr. 4, 2025) (denying request for deposition of a witness in an individual capacity, on basis that deposing party should have combined such a deposition with the 30(b)(6) deposition of the same person)

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Steward, a bankrupt healthcare organization, is set to sell its physician group to a private equity firm for $245 million. Kaiser's operating margin has risen to 3.1% in the second quarter, indicating a strong performance for the nonprofit giant. Stryker is acquiring smart hospital technology firm care.ai to enhance its health IT offering. For-profit health systems have seen an increase in Medicaid supplemental payments in the second quarter, although executives state it is not enough to cover costs. The importance of integrating generative AI in the healthcare landscape is highlighted, with tips on selecting the right vendor for AI solutions. The newsletter also includes insights on using data to improve patient outcomes and transforming healthcare through tailored change management strategies.Transitioning to the next news segment:Lilly has opened a new R&D hub in Boston, while Ovid and Lexicon have laid off staff. Biotech M&A activity is increasing, with Crown Laboratories acquiring Revance Therapeutics. Galderma has received FDA approval for Nemluvio, a competitor to Dupixent for treating prurigo nodularis. Biotech IPOs are crucial for the industry, with Actuate Therapeutics recently pricing its IPO. A journal retracted papers on MDMA-assisted therapy following FDA rejection. Companies like Pfizer and Lilly are focusing on patient-centric commercialization strategies. Key events include a webinar on increasing a drug's chances of reaching the commercial market and company announcements from Procdna, Authenticx, and others.Moving on to the next segment:Atai, a biopharmaceutical company, has seen early success with its psychedelic depression drug in a phase Ib study. This comes after the FDA rejected another company's MDMA-assisted PTSD therapy. Galderma's IL-31 injection has received FDA approval for the skin disorder prurigo nodularis, with potential for use in atopic dermatitis. Novo Nordisk is continuing to pursue its insulin icodec program, aiming to file a combination with semaglutide by the end of the year. Q2 earnings for biopharma companies have been mixed, with some exceeding expectations while others faced challenges due to the COVID-19 pandemic and vaccine issues. The role of Quality Assurance and Regulatory Affairs (QARA) professionals is becoming increasingly important in the biopharma industry, transitioning from the factory floor to the boardroom.Transitioning smoothly to the next news:Gain Therapeutics is making strides in developing a potential treatment for Parkinson's disease that targets alpha synuclein through a small molecule that binds to an enzyme coded by a specific gene. This approach aims to modulate the underlying biology of the disease. The company's chief medical officer, Dr. Jonas Hannestad, emphasized the importance of biomarkers in neurodegenerative drug development to monitor the effectiveness of treatments. Gain Therapeutics faces challenges in financing, but their innovative approach could change how Parkinson's disease is treated.Additionally, an emerging drug candidate for multiple sclerosis from Immunic has shown promising safety and antiviral effects.Transitioning smoothly again:Liquid I.V. is running a multichannel campaign called "Indulge in Hydration" to help consumers beat the summer heat. The campaign includes augmented reality activations, Netflix ad testing, and a Spotify takeover. Oreo and Coca-Cola have partnered to create a drink and cookie combination featuring the iconic brands, with a marketing campaign centered around "besties." LG is boosting its home appliances with a competition show on Prime Video called "Estate of Survival." WPP has downgraded its full-year outlook as it works to modernize its offering.Concluding this episode:This week in biotech Support the Show.

Longest-reigning British monarch led U.K. through eras of change. Plus: U.S. stocks end higher amid new Federal Reserve comments. European Central Bank raises interest rates by historic 0.75 point. FDA approves Revance Therapeutics' Botox rival Daxxify. Rivian, Mercedes to partner on electric-van factory. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host Dr. John Sweetenham, of the UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and Dr. Bridgette Thom, of the Memorial Sloan Kettering Cancer Center, discuss a novel intervention to address financial toxicity and social need using the Electronic Medical Record.   TRANSCRIPT Dr. John Sweetenham: Hello. I'm Dr. John Sweetenham, the associate director for clinical affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast. My guest today is Dr. Bridgette Thom, a researcher at Memorial Sloan Kettering (MSK) Cancer Center. We'll be discussing a novel approach to address financial toxicity that uses the electronic medical record to streamline referrals to financial assistance and counseling for high-risk patients. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts. Dr. Thom, it's great to have you on the podcast today. Dr. Bridgette Thom: Thanks so much for having me. Dr. John Sweetenham: Dr. Thom, the high costs of cancer care have caused major financial distress for many patients and their families. And this, of course, has been the subject of a great deal of literature in recent years. As you noted in your poster presentation at the recent ASCO Annual Meeting, there are limited interventions, despite a need for patient level and system-based solutions (Abstract 6596). Listeners to our podcast will remember a previous discussion that we had with Dr. Derek Raghavan from the Levine Cancer Institute, where they had instituted financial toxicity grand rounds to partially address this problem. Can you tell us about the novel approach that you and your colleagues explored using the electronic medical record to streamline referrals for financial assistance and counseling? Dr. Bridgette Thom: I first have to credit our team for this work. Dr. Emeline Aviki, who is a gynecological surgical oncologist with keen interest in affordability and payment models, founded the MSK affordability working group several years ago. The first priority of the group was to determine the scope of financial hardship at our institution. At the time, we were absent a systematic screening process. So she, our data analysts, and representatives from our Patient Financial Services Program, developed proxy measures to figure out which patients might be having financial issues. Looking through the medical record, we found those patients who had used one of our Patient Financial Services assistance programs, those who had billing issues, and those who had been referred specifically to social work for a financial issue. And in doing so, we found out that about 25% of our patients over a 2-year period were facing some sort of financial issue. Looking closer at that data, patients experiencing financial hardship weren't necessarily being connected to the resources that we had available, which include copay assistance programs, financial assistance programs, and support for non-medical essential needs. So, for example, we had about 1 in 6 patients who had some sort of payment issue, but only about 20% of them had applied for financial assistance. And we wanted to figure out why this was happening and review the process. In doing so, we discovered that too much burden was being placed on already burdened social workers who had to triage all those issues. So Dr. Aviki in her wisdom realized that care providers, physicians, advanced practice providers (APP), nurses needed to make direct referrals to the resources that we had. So we had a place for patients to go, we just needed an easier mechanism for them to get there. And that was the birth of the financial toxicity order set. And she and her team really powered through the developmental and testing phases working with IT, our strategy administration groups, clinical end users, our PFS team, that's Patient Financial Services. We built this order set that allows clinicians directly to refer to our resources. So clinicians, either through their discussions with patients or if patients bring up an issue, through the order set they can select a reason for a referral, the urgency of referral, the clinical location, etc. And then those orders go directly to our Patient Financial Services staff who then contact patients. We piloted this program in late 2020, early 2021 on 1 service, and then used that feedback to roll out the program first to our outpatient clinics and then to inpatient. That process involved a lot of educational efforts, getting the word out, and working with IT and our strategy team to stay on top of the data and monitor referrals over time. Dr. John Sweetenham: Thanks. Could you say just a little bit more about the educational process that you use? I noticed in looking at your poster that the bulk of referrals came either from the clinic nurse or from the APP. Did you tailor your education in any way to the specific provider that was involved? How did you do that piece? Dr. Bridgette Thom: Our affordability working group is an interdisciplinary team and we have nurses, social workers, physicians. So we did a lot of grand rounds work tailored to the audience be it by disease type or clinical role. Dr. John Sweetenham: Great, thank you. This is clearly great work. There's a lot of useful and helpful information in your abstract and in your poster. What would you say are the key takeaways from the intervention? What would you say about the scalability of this approach into community practice as opposed to a very large institution such as yours? Dr. Bridgette Thom: One key takeaway from a process perspective was the need, like I said, for an interdisciplinary approach to handling the issues. That might seem obvious, but it was really crucial to the success of the project to engage key departmental stakeholders and decision makers very early in the process and keep them informed throughout the development of the order set. That definitely helped us to smooth a potentially bumpy road when we're dealing with big systems change. From an outcomes perspective, a key takeaway is the importance of having actionable items to empower the care providers. So while our institution has this amazing program, our Patient Financial Services program which provides counseling, and connects patients to tangible resources, this type of intervention I think could be scalable or applicable to a community practice or smaller hospital, provided there's somebody, a social worker, patient navigator, [or] nurse, that can be a connection for patients and those potential resources that do exist out there. For us going forward, we're going to continue to evaluate the order set, both from the clinical end user and then also the Patient Financial Services staff to learn more about their perspectives and what can be adapted in the order. We also, of course, want to learn from our patients about their experience with the process, and so we have projects, both research and program evaluation, in the works to consider their perspective. Dr. John Sweetenham: Great, thank you. And I guess 1 of the other aspects of this where there is obviously substantial opportunity is that, of course, currently, you're still reliant upon the provider to place the order. And I wonder whether you feel that some form of screening for social need and financial hardship could be embedded within the electronic health record as a key next step, so that you proactively identify those high-risk patients. Dr. Bridgette Thom: Definitely. And that is, in fact, our next step. We are currently piloting our financial hardship screening tool on 4 large services at our institution. The objective here is to, like you said, proactively identify patients who might be at risk and connect them to resources, be it tangible resources, or just counseling or insurance guidance, [and] do that before the hardship can occur. And the goals of our pilot phase are to (1) develop and refine a tool that's both predictive, but also feasible to administer within a busy clinic setting. And then also (2) to work with our interdisciplinary team to adapt the workflow. We can have a great tool, but if we don't have a way to administer it in a clinic, it's not going to do us any good. So for us, that means listening to feedback from, first and foremost, our patients and then the key stakeholders in the process. Our nurses have been integral to this process. We also, of course, our Patient Financial Services, staff, the clinical operations staff, obviously, IT, social work. And once we have these processes figured out and we have our tool solid, we will hopefully expand the screening to all services, and then use data to figure out the optimal screening interviews by disease and treatment type because we feel that this could vary by a patient's treatment trajectory. Dr. John Sweetenham: You note in your poster that additional multilevel interventions are needed to address the problem of financial toxicity at a systems level, and of course, what you have done here is a really great and important step in helping to identify those patients. But identifying those patients who are at particular risk is only beginning of addressing the issue. Could you elaborate a little bit more on other areas that you're exploring in terms of the interventions that you're using? Dr. Bridgette Thom: Sure. And this idea of multi-level interventions comes from my social work training, where there's an emphasis on viewing the individual as being part of a series of dynamic and interconnected relationships and systems: the social ecological theory. So if we think of concentric circles with the patient at the center, there are cascading relationships that are going to impact the course of their care. We radiate out to families and caregivers, a patient's workplace if they're employed, the hospital and the providers there, and then look to bigger systems where a patient lives, their town. If it's in an urban setting or a rural setting, the type of insurance that they have, if it comes from their employer, or if it's a different insurance system, their community and then of course, broader, social, societal, more macro issues. My point and that of many others who work in this space is that we have to consider the context. We can't just build and test interventions that focus on a patient because the patient isn't existing in a bubble. They're existing in relationships with their caregivers, their health care providers, their health care system. And all of that exists in, for lack of a better word, a broken system of structural inequality, systemic racism, and conflicting values about health care as a right. Patient-level interventions are indeed important, but we can't place the burden solely on the patient. And we, as researchers and clinicians in this space, really need solutions that are going to reach across systems. I think, like you said, this project demonstrates that and this is something that I hear from patients in other work that I'm doing. For example, I'm working on a digital intervention to help young adult cancer survivors to build their financial capability and build their understanding of the health care system and insurance systems and financing and all of that. As I co-develop this intervention with patients and survivors, I'm hearing, 'This is great. I'm glad I'm learning these things, but at the same time, my co-pays are unmanageable,' Or, 'I might have to skip my survivorship appointment because I can't afford to take off work that day.' I think we have to really think about, like I said, the context and the bigger picture of the scope of the problem and build and develop interventions that acknowledge that. Dr. John Sweetenham: Well, as you say, very complex, multi-level problem and many interventions needed. But congratulations and kudos to you and your colleagues for addressing one component of this. And we're really looking forward to seeing how this develops and progresses in the coming years. And I'd like to thank you, again, for sharing your insights with us today on the ASCO Daily News podcast and telling us a little bit more about this great work. Dr. Bridgette Thom: Thank you so much for having me. I want to just acknowledge all of the work of our team. It has really been a team effort. We're looking forward to our next steps. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the poster discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. You can hear more about the MSK Affordability Working Group's efforts on the podcast, Cancer Straight Talk from MSK.   Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Bridgette Thom: Stock and Other Ownership Interests (Immediate Family Member): Caladrius Biosciences, Mediwound, Sierra Oncology, Lipocine, MEI Pharma, Oncternal Therapeutics, Avadel Pharmaceuticals, Chimerix, Avidity Biosciences, Sutro Biopharma, Adma Pharma, Concert Pharmaceuticals, Processa Pharmaceuticals, Curis           An, IMV, Arcus Biosciences, Iovance Biotherapeutics, Qiagen, Revance Therapeutics, DermTech, Zimmer BioMet, Axonics Modulation, Halozyme, Autolus, Pavmed Inc       , Mereo BioPharma, and AADi Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, our single stock focus - Revance Therapeutics - and other key events that could impact stocks. Learn more about your ad choices. Visit megaphone.fm/adchoices

A California-based company moves into Nashville and takes over the top of The Gulch. Are you in the market for a hotel? Several of Nashville’s largest hotels have hit the market. Plus, the East Bank is rolling along quickly with new renovations and more money poured into the area.Become a subscriber! Visit us at https://www.patreon.com/nashvilledailyTEXT US: 615-392-1358Today's Sponsor: Screened ThreadsUse the Code "NashvilleDaily" for 10% off online and in-storehttps://screenedthreads.com/Nash NewsNashville COVID-19 Responsehttps://www.asafenashville.org/Botox alternative Revance Therapeutics moves headquarters to Gulch office tower, forecasts 150 jobs in five yearshttps://www.bizjournals.com/nashville/news/2020/12/16/revance-therapeutics-hq-move-ceo-mark-foley.htmlAshford Hospitality Trust puts downtown Renaissance Hotel on the markethttps://www.bizjournals.com/nashville/news/2020/12/15/renaissance-on-the-market.htmlSheraton Downtown For Salehttps://www.bizjournals.com/nashville/news/2020/12/18/sheraton-downtown.html?ana=TRUEANTHEMFB_NA&csrc=6398&utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=facebook&fbclid=IwAR1ExwEhFIxWvNK2gq3qTtbQL_48s8bs7W3Lj4D_ExbcDsC8ehBpzA5tbOchttps://wpln.org/post/curious-nashville-whatever-happened-to-nashvilles-revolving-restaurant/Exclusive: Concept images for potential Nissan Stadium renovations released as Titans gauge fan feedbackhttps://www.bizjournals.com/nashville/news/2020/12/21/titans-nissan-stadium-renovations-east-bank.htmlLocal Artist Feature - Jon MullinsBetter Manhttps://open.spotify.com/artist/3MKuZm9eAVMdw9ni14mzCPhttps://www.jonmullins.comNashville Daily Artist of the Day Playlisthttps://open.spotify.com/playlist/51eNcUWPg7qtj8KECrbuwx?si=nEfxeOgmTv6rFUyhVUJY9AFollow us @ XPLR NASHWebsite -  https://nashvilledailypodcast.com/YouTube Channel - https://www.youtube.com/c/xplrnashInstagram - https://www.instagram.com/xplr.nash/Twiter - https://twitter.com/xplr_nashNASHVILLE & XPLR MERCH - http://bit.ly/nashville_merchMedia and other inquiries please email hello@xplr.lifeArtists can submit songs to be featured here https://forms.gle/mtkxUCFds7g9e2466

As a top plastic surgeon in Houston, Texas, Dr. Camille Cash is recognized by patients and peers alike as a leader in her field. Dr. Cash is known for her unique and innovative techniques to achieve a natural and improved look. She combines the use of surgery with non-surgical or minimally invasive procedures to yield the best outcomes for transformation and empowerment, including body contouring, facial and breast sculpting, anti-aging regimens, and vaginal rejuvenation for women. “Plastic surgery to me, embodies the perfect combination of artistry with medicine, fine details with the big picture, instant gratification with lasting change, new technologies with tried-and-true standards.” A trailblazer in her field, Dr. Cash is Double Board certified in both General Surgery and Plastic Surgery and was the first African American female in the State of Texas to achieve this distinction.  Dr. Cash's extensive training began at Howard University where she graduated magna cum laude before earning her medical degree at Baylor College of Medicine. She completed a five-year general surgery residency and a two-year plastic surgery residency at St. Joseph Hospital where she earned the prestigious Resident of the Year Award. In 2002, Dr. Cash founded her solo private practice and has gone on to establish herself as a leading provider of the newest and most advanced technologies and techniques for surgical and non-surgical cosmetic enhancement. Dr. Cash's sought-after expertise has led to numerous interviews for local and national print, digital, and television media. Dr. Cash was featured throughout season three of the TLC series My 600lb Life: Skin Tight where she showcased her surgical skill and bedside manner in treating patients suffering with excess skin following massive weight loss. Dr. Cash has consistently been named as a Top Doctor by the medical review site, RealSelf, and is ranked among the top 1% of participating medical professionals on the prestigious RealSelf 100 List. She was also recently named one of the top three plastic surgeons in Houston by the selection committee for Three Best Rated, a consumer review site focused on local business. Recognized for sharing her knowledge and commitment to patient education and optimal patient outcomes, Dr. Cash participated as an investigator for the Allergan Breast Implant Follow Up Study, among other clinical trials. Dr. Cash also serves as a medical advisor and educator with leading industry partners including SkinCeuticals®, Neodyne Biosciences, Revance Therapeutics®, InMode, Healeon Medical, Regeneris Medical® and CareStream America. Even with her thriving private practice and busy family life, Dr. Cash continues to devote time to causes that are important to her. Dr. Cash believes in giving back to her community as an active member of Alpha Kappa Alpha Sorority, Inc., St. Mary of the Purification Catholic Church and as a board member for St. Agnes Academy and Sisters Network® Inc. Dr. Cash also stays active in the plastic surgery community through her ongoing participation in such organizations as The American Society for Aesthetic Plastic Surgery and The Texas Society of Plastic Surgeons. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/humovemakers/message Support this podcast: https://anchor.fm/humovemakers/support

Niqui has over 25 years experience in developing, launching and commercially scaling 20+ products in both large corporations (P&G, Warner Lambert) and early stage companies across multiple verticals in the consumer medicine market. Every business she managed has increased sales, profits and/or market share. Prior to Candesant, she led the commercial strategy at Revance Therapeutics and helped raise over $250M in the company’s 2014 IPO and follow-on financing.

Drs. Sam Jejurikar, Salvatore Pacella, and Sam Rhee talk about cosmetic surgery for men. They cover why men get cosmetic surgery and why it is different than for women. Dr. Salvatore Pacella shares a great facial rejuvenation case as well as a gynecomastia (breast reduction) case. They also talk about non-surgical rejuvenation with Botox and fillers such as Juvederm and Restylane for men as well as a new, longer lasting Botox alternative in the pipeline from Revance Therapeutics called DAXI (daxibotulinumtoxin).

Today is a very exciting day! We will be discussing a new longer-lasting neuromodulator. In other words a longer-lasting "Botox". We will be sitting down with Mark Foley the President and CEO of Revance, the company that is bringing this new product to the market. Listen in as we share the latest and greatest info! More info on Mark... Mark Foley is currently the President and CEO of Revance Therapeutics and has served as a member of the Company's board of directors since September 2017. Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ's growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company's stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018. Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies. Mr. Foley currently serves on the board of directors of Glaukos (GKOS), Si-Bone (SIBN) and as chairman of the board for ULab and HintMD. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame in 1987 and is a named inventor on 17 patent applications. --- Send in a voice message: https://anchor.fm/janet-allenby/message

Niquette Hunt, CEO, Candesant Biomedical Niquette Hunt, CEO, has over twenty-five years' experience in developing, launching and commercializing 20+ products across multiple verticals in the consumer medicine market. Every business she managed increased sales, profits and/or market share. Before founding Candesant, Ms. Hunt charted the commercial strategy at Revance Therapeutics and helped raise over $250 million in the 2014 IPO and follow-on financing.

In this podcast, AIS Co-Chair Mark Foley - a successful executive in his own right - asks Dan Browne, CEO of Revance Therapeutics several compelling questions.How did his love for the outdoors lead to his career in medical technology? What led him to co-found Revance with two friends? What were some of the important “pivot points” in building this exciting aesthetics company? What’s next for Revance following last week’s exciting news about its long-acting neuromodulator DaxibotulinumtoxinA for Injection (RT002).

Today in FirstWord:

Today in FirstWord: